May 15, 2022 · In this multicenter, randomized, double-blind, phase 2 trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of PDE4B, 17 in patients with IPF according...

In the present paper, the preclinical pharmacology of the novel PDE4 inhibitor BI 1015550 is characterized, with results suggesting that this compound has potential for the treatment of IPF and probably other fibrotic ILDs.

May 15, 2022 · Currently approved treatments for idiopathic pulmonary fibrosis slow, but do not stop, progression of the disease. Additional treatments are needed. New research findings are summarized in a...

May 15, 2022 · Background: Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis.

Aug 18, 2023 · There is an unmet need for new treatments for idiopathic pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study in patients with IPF.

Preferential inhibition of phosphodiesterase 4 (PDE4) B in patients with pulmonary fibrosis could provide anti-inflammatory and antifibrotic effects with improved safety compared with pan-PDE4 inhibitors. https://bit.ly/3UE0CdU

Jan 2, 2025 · The preferential PDE4B inhibitor nerandomilast demonstrated efficacy in preserving lung function in a phase II trial in patients with IPF and is under investigation in phase III trials as a treatment for IPF and PPF.

Phosphodiesterase 4 (PDE4) inhibition is known for its anti-inflammatory and antifibrotic properties. BI 1015550, an oral preferential inhibitor of the isoform PDE4B, could express complementary activity to current therapies in IPF and other …

BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF).

Oct 26, 2022 · FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (ILDs)